DARMSTADT, Germany & New York, Sept 25 (Bernama-BUSINESS WIRE) --As part of the global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab*, an investigational immune checkpoint inhibitor, the companies have announced today that they have a collaboration agreement in place with Dako, an Agilent Technologies company, for the development of a potential companion diagnostic test (CDx).
No comments:
Post a Comment